A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.

NCT05322577 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Cancer
Gastroesophageal Junction Cancer

Interventions

DRUG: Bemarituzumab
DRUG: CAPOX
DRUG: SOX
DRUG: Nivolumab

Sponsor

Amgen